The current standard-of-care, sorafenib, a multikinase inhibitor, inhibits tumor angiogenesis and induces apoptosis in HCC by blocking the RAF/MEK/ERK pathway, one of the key functional pathways of HCC development [38]. Here, MAP2K7 is linked to neoplasm.